{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:31:45Z","timestamp":1783625505601,"version":"3.55.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12-CA-076931"],"award-info":[{"award-number":["K12-CA-076931"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.hoc.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:39:45Z","timestamp":1656463185000},"page":"701-727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chimeric Antigen Receptor T-cell Therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Aimee C.","family":"Talleur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Shalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2022.03.005_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.005_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2014.177","article-title":"Immune-based therapies for childhood cancer","volume":"11","author":"Mackall","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2022.03.005_bib3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2022.03.005_bib4","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T\u00a0cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2022.03.005_bib6","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T\u00a0cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"9967","key":"10.1016\/j.hoc.2022.03.005_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hoc.2022.03.005_bib8","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-Cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2022.03.005_bib9","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2022.03.005_bib10","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10266","key":"10.1016\/j.hoc.2022.03.005_bib11","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T\u00a0cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"9967","key":"10.1016\/j.hoc.2022.03.005_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T\u00a0cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.005_bib15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.005_bib16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.005_bib17","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T\u00a0cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2022.03.005_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.hoc.2022.03.005_bib22","first-page":"1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"16 Supplement","key":"10.1016\/j.hoc.2022.03.005_bib23","doi-asserted-by":"crossref","first-page":"CT051","DOI":"10.1158\/1538-7445.AM2020-CT051","article-title":"Abstract CT051: Safety and efficacy of CD19\/CD22 CAR T\u00a0cells in children and young adults with relapsed\/refractory ALL","volume":"80","author":"Shalabi","year":"2020","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib24","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2022.03.005_bib25","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2020.38.15_suppl.3035","article-title":"Efficacy of SCRI-CAR19x22 T\u00a0cell product in B-ALL and persistence of anti-CD22 activity","volume":"38","author":"Gardner","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib26","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/HS9.0000000000000279","article-title":"Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL","volume":"3","author":"DiNofia","year":"2019","journal-title":"Hemasphere"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.005_bib27","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib29","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T\u00a0cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.005_bib31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.005_bib32","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.hoc.2022.03.005_bib34","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.005_bib35","first-page":"350","article-title":"Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J\u00a0Immunother"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNP.0000000000000669","article-title":"EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity","volume":"38","author":"Gust","year":"2019","journal-title":"J\u00a0Clin Neurophysiol"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T\u00a0cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"10.1016\/j.hoc.2022.03.005_bib40","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1080\/10428194.2021.1924370","article-title":"Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome","volume":"62","author":"Banerjee","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2022.03.005_bib41","first-page":"705","article-title":"Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.hoc.2022.03.005_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib43","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000515","article-title":"Cytokine release syndrome biology and management","volume":"27","author":"Cobb","year":"2021","journal-title":"Cancer J"},{"issue":"19","key":"10.1016\/j.hoc.2022.03.005_bib45","doi-asserted-by":"crossref","first-page":"e25786","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T\u00a0cell therapy for patients with refractory acute lymphoblastic leukemia: A case report","volume":"100","author":"Zi","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib46","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T Cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib47","first-page":"78","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib48","doi-asserted-by":"crossref","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.005_bib49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor t\u00a0cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib50","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib52","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2022.03.005_bib53","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.005_bib54","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T\u00a0cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.005_bib55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2022.03.005_bib56","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2022.03.005_bib57","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib58","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.005_bib60","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious Complications of CAR T-Cell Therapy Across Novel Antigen Targets in the first 30\u00a0days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib61","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.005_bib63","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T\u00a0cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.005_bib64","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.hoc.2022.03.005_bib65","doi-asserted-by":"crossref","first-page":"845540","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Frontiers in oncology"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib66","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41409-020-01027-6","article-title":"Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia","volume":"56","author":"Deya-Martinez","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.hoc.2022.03.005_bib67","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib68","first-page":"e003428","article-title":"Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy","volume":"9","author":"Walti","year":"2021","journal-title":"medRxiv"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.005_bib69","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib70","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.005_bib71","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2017-12-822940","article-title":"False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy","volume":"131","author":"Laetsch","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2022.03.005_bib72","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib73","doi-asserted-by":"crossref","first-page":"e001563","DOI":"10.1136\/jitc-2020-001563","article-title":"Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"8","author":"Mo","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2022.03.005_bib74","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2017-09-804070","article-title":"Anti-CD19 resistance can \"stem\" from progenitors","volume":"130","author":"Shah","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.005_bib75","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T\u00a0cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"issue":"320","key":"10.1016\/j.hoc.2022.03.005_bib76","doi-asserted-by":"crossref","first-page":"320ra323","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T\u00a0cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib78","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T\u00a0cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib79","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2022.03.005_bib80","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2019-130796","article-title":"Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance","volume":"134","author":"Masih","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.005_bib81","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib82","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.005_bib83","doi-asserted-by":"crossref","first-page":"e00383-18","DOI":"10.1128\/MCB.00383-18","article-title":"CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.005_bib84","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.005_bib85","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib86","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib87","doi-asserted-by":"crossref","first-page":"73.e1","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of high disease burden on survival in pediatric patients with B-all treated with tisagenlecleucel","volume":"28","author":"Ravich","year":"2021","journal-title":"Transplantation and Cell Ther"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib88","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2022.03.005_bib89","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib90","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T\u00a0cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib91","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"511","key":"10.1016\/j.hoc.2022.03.005_bib92","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T\u00a0cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib93","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2021-153336","article-title":"KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy","volume":"138","author":"Lamble","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.005_bib94","doi-asserted-by":"crossref","first-page":"110079","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T\u00a0cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.005_bib95","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"s1","key":"10.1016\/j.hoc.2022.03.005_bib96","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2021-147299","article-title":"Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T\u00a0cells in children and young adults with relapsed\/refractroy B-cell acute lymphoblastic leukemia","volume":"138","author":"Myers","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib97","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2022.03.005_bib98","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2019-131346","article-title":"Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In\u00a0Vivo","volume":"134","author":"Annesley","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage","volume":"28","author":"Summers","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"23","key":"10.1016\/j.hoc.2022.03.005_bib100","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood.V126.23.3769.3769","article-title":"Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS\/Combined Relapsed\/Refractory ALL","volume":"126","author":"Rheingold","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2022.03.005_bib101","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bbmt.2020.07.036","article-title":"Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia","volume":"26","author":"Rubinstein","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib102","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel Outcomes in Relapsed\/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2022.03.005_bib103","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.005_bib104","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.005_bib105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T\u00a0cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2022.03.005_bib106","first-page":"130","article-title":"Marked Re-Expansion of Chimeric Antigen Receptor (CAR) T Cells and tumor regression following nivolumab treatment in a patient treated with axicabtagene ciloleucel (axi-cel; KTE-C19) for Refractory Diffuse Large B Cell Lymphoma (DLBCL)","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.hoc.2022.03.005_bib108","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.005_bib110","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation Therapy as a Bridging Strategy for CAR T\u00a0cell therapy with axicabtagene ciloleucel in diffuse large B-Cell Lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.005_bib111","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of Extramedullary Disease in B-ALL and Response to CAR T-cell Therapy","volume":"6","author":"Holland","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2022.03.005_bib112","doi-asserted-by":"crossref","unstructured":"Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 2017;127(9):3462\u201371.","DOI":"10.1172\/JCI94306"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.005_bib113","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt Lymphoma","volume":"6","author":"Liu","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2021-146302","article-title":"Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell therapy for pediatric refractory\/relapsed burkitt lymphoma with secondary central nervous system involvement","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.005_bib115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T\u00a0cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.005_bib116","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.005_bib117","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T\u00a0cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.005_bib118","doi-asserted-by":"crossref","first-page":"e1407898","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T\u00a0cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.005_bib119","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T\u00a0cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"Sanchez-Martinez","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.005_bib120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T\u00a0cell receptor beta-chain constant region for immunotherapy of T\u00a0cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"35","key":"10.1016\/j.hoc.2022.03.005_bib121","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T\u00a0cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.005_bib122","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.005_bib123","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"30","key":"10.1016\/j.hoc.2022.03.005_bib124","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2021-147667","article-title":"High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R\/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib126","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2021-147754","article-title":"A\u00a0novel and successful patient or donor-derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R\/R T-LBL)","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib127","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2021-154142","article-title":"Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-Cells in patients with refractory\/relapsed T-Cell Lymphoma","volume":"138","author":"Rouce","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.005_bib128","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2022.03.005_bib129","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A\u00a0Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2022.03.005_bib130","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2021-146534","article-title":"A\u00a0comparison study of anti-CLL1 CART Cells equipped with different co-stimulatory domains in the treatment of children with refractory\/relapsed acute myeloid leukemia","volume":"138","author":"PEI","year":"2021","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:17:47Z","timestamp":1760185067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889858822000260"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}